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Subrenal capsule assay in selection of chemotherapy after operation for
recurrent ovarian cancer
P. Venesmaa & 0. Ylikorkala
I and II Department ofObstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Summary Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the
subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the
remaining 23 control patients. The SRCA was evaluable in 22 cases (96%). Taken together, no significant
difference appeared in the 3 years' survival figures between the groups: seven of 22 patients (32%) with the
evaluable SRCA and six of 23 control patients (26%) were alive. However, a further analysis of the data
revealed that the SRCA guided the selection of chemotherapy only in 15 patients, whereas tumour samples
were resistant to all cytostatics tested in six cases and toxic side-effects limited the clinical application of the
test results in the remaining one case. Four of the 11 patients (36%) whose further chemotherapy was strictly
chosen based on the SRCA and seven of the 24 patients (29%) whose treatment was based on physician's
choice survived at least 3 years. Our conclusion is that the SRCA is of limited value in the selection of
second-line chemotherapy in recurrent ovarian cancer.
The subrenal capsule assay (SRCA) (Bogden et al., 1981)
correctly predicts the response to cytostatic chemotherapy in
63-85% of patients with previously untreated ovarian cancer
(Bogden, 1985; Griffin et al., 1983; Maenpaa et al., 1985a,b;
Stratton et al., 1984, 1986, 1988). The situation may differ in
cases with recurrent cancer, when cell populations resistant to
first-line chemotherapy have become selected out to form
clinically detectable tumours (Maenpaa, 1985c). There are
some data to suggest that the SRCA could be useful in the
selection of the second-line chemotherapy (Griffin et al.,
1983; Maenpaa, 1985c), but so far no data exist on improved
survival rates in patients whose second-line chemotherapy
has been guided by the use of the SRCA. We therefore
assessed the value of the SRCA in patients with recurrent
ovarian cancer that were followed up to death or for a
minimum of 3 years.
Materials and methods
Forty-six patients between 25 and 76 years of age with
recurrent ovarian cancer were studied (Table I). The primary
operation was radical in seven women, whereas tumours
smaller than 2 cm of size remained in nine women and
tumours larger than 2cm remained in 30 women. Serous
cystadenocarcinoma was the most common type of cancer
(22 women) followed by anaplastic cancer (11 women),
miscellaneous cancer (nine women with mesonephric cancers
and one with endometrioid cancer) and mucinous cystadeno-
carcinoma (three women) (Table I). The cancer had spread to
clinical stages III-IV in 37 women. All patients following
surgery had been treated with 4-28 courses of various cyto-
statics, mostly with the combination of doxorubicin, cisplatin
and cyclophosphamide (n = 34 patients). Thirty-five had
responded favourably to the therapy, as assessed by the
standard criteria (Miller et al., 1981), whereas in 11 women
no response to therapy and/or progression of the disease was
seen.
These 46 patients entered our study with the approval of
the local committee of ethics between 5-48 months after
primary operation, when they came for a routine second-look
(n = 32) and third-look (n = 6) laparotomy or a debulking
operation (n = 8). At operation 19 patients had residual
tumour of size 2 cm or less (after operation no macroscopic
tumour in six women), whereas 27 women had tumours
larger than 2 cm (after operation no macroscopic tumour in
four women and tumour less than 2 cm in six women). At
this operation samples of histologically confirmed cancer
were collected for the SRCA in 23 patients (operated on
Monday-Wednesday), whereas this was not possible in 23
comparable control patients (operated on Thursday-Friday).
The two groups were comparable as regards various clinical
variables (Table I).
The tumour samples were put immediately into sterile
tubes containing medium 199 and transported to the labora-
tory for the SRCA, as described in detail previously (Kangas
& Perila, 1985). The samples were cut into 1 mm3 pieces and
implanted under the renal capsules of 30 mice which were
then treated with five vanrous cytostatic combinations (five
mice for each) or served as a control group (five mice).
Cisplatin-doxorubicin-cyclophosphamide, cisplatin-hexame-
thylmelamine-melphalan and cisplatin-etoposide-hexamethyl-
melamine were the most frequent combinations tested (Table
II). Response was judged by difference in tumour size
between the untreated control and treated mice, and results
were interpreted as sensitive if the mean tumour size had
decreased by 1 omu (omu = ocular micrometer unit, 10
omu = 1 mm) or more, intermediately sensitive if the mean
tumour size had decreased by less than 1 omu or increased
by less than one-third of the ATS (ATS = difference
between the initial and final tumour size) in the control
group, and resistant if the mean ATS was one-third or more
of that in the control group (Maenpaa et al., 1985b).
The results of the SRCA were used in selecting chemo-
therapy after reoperation, whereas in the control group
therapy was chosen based on clinical experience.
Results
One patient had serous cystadenocarcinoma which did not
grow in control mice and this test was discarded. Thus 22 of
23 tests (96%) were evaluable.
Cancer samples of ten patients (45%) were resistant to the
combination of cisplatin-doxorubicin (or epiadriamycin)-
cyclophosphamide or to the combination of cisplatin-hexa-
methylmelamine-melphalan (Table II). Taken together, four
patients (18%) had sensitive tumours, 13 (59%) had tumours
of intermediate sensitivity at least to one combination tested,
whereas samples from six patients (27%) were resistant to all
combinations tested (Table II).
The use of the SRCA directed the selection of chemo-
therapy totally in 11 patients and partly in four patients; in
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Table I Clinical characteristics of the study population
Number of patients
Age (median, range)
Stage
I-II
III-IV
Histology
Serous cystadenocarcinoma
Mucinous cystadenocarcinoma
Anaplastic cancer
Miscellaneous cancer
Time from primary operation to
reoperation (months)
(median, range)
Tumour size at reoperation
Tumour size <2 cm
Tumour size >2 cm
Primary
operation
46
55 (25-76)
9
37
22
3
11
10
Reoperation
SRCA done SRCA not done
23 23
55 (25-76) 55 (27-71)
6
17
12
2
5
4
3
20
10
1
6
6
16 (7-47) 16 (5-49)
10
13
9
14
Type of reoperation
Second look
Third look
Debulking
16
3
4
16
3
4
Table II The sensitivity of the tumour in the SRCA in 23 patients in relation to previous and consequent cytotoxic treatment
Sensitivity of the tumour in the SRCA
DDP DDP DDP DDP DDP DDP DDP DDP DDP
Patient's Drug combination A HMM HMM EPIA A EPIA CTX 5-FU MTX Drug combination The SRCA directed
initials before reoperation CTX VP16 LPAM CTX HMMHMMACLA HMM 5-FU after reoperation chemotherapy
M.A.* DDP-A-CTX I I I DDP-A-CTX Yes
M.G.* DDP-A-CTX I I I DDP-A-CTX Yes
P.A. DDP-A-CTX I I I DDP-A-CTX Yes
K.I. DDP-A-CTX I I S - I I DDP-A-CTX Yes
M.M. DDP-A-CTX I I I - DDP-A-CTX Yes
A.U.* DDP-A-CTX I I R - I R DDP-A-CTX-HMM Yes
J.R.* DDP-A-CTX I R I - R I DDP-LPAM-HMM Yes
T.A. DDP-A-CTX I S - I I DDP-LPAM-HMM Yes
R.A. DDP-A-CTX I I R I I DDP-LPAM-HMM Yes
A.T. DDP-A-CTX R I R R R - - DDP-VP16-HMM Yes
T.N. DDP-A-CTX I S I I S DDP-MTX-5-FU Yes
B.A.* DDP-CTX S I I I I DDP-CTX-HMM Partly (see text)
F.A. 5-FU-A-CTX R - I I I - DDP-LPAM Partly (see text)
P.M. 5-FU-A-CTX R R I _ R R - - DDP-LPAM-VP16 Partly (see text)
G.S. DDP-A-CTX I I R - - - _ _ CAR-HMM Partly (see text)
IA.' DDP-VP16-HMM R R R - - - - - DDP-VP16-HMM No
H.K. DDP-A-CTX R R R - - - - - CAR-CTX No
S.S. DDP-A-CTX R R R - - - - - DDP-CTX No
U.I.* DDP-A-CTX R R R - - - - - DDP-A-CTX No
R.S. DDP-A-CTX R R R - - - - - DDP-A-CTX No
V.H. DDP-A-CTX R R R - - - DDP-A-CTX No
A.K. DDP-A-CTX - R R I - R R MTX-5-FU No
H.R.* 5-FU-A-CTX This test was discarded because tumour sample did not grow in control mice. DDP-A-CTX
patient surviving 3 years; S = sensitive; I = intermediately sensitive; R = resistant to cytostatics in the SRCA; - = not tested; A = dox-
orubucin; Acda = aclarubicin; CAR = carboplatin; CTX = cyclophosphamide; DDP = cisplatin, EPIA = epiadriamycin; 5-FU = 5-fluorouracil;
HMM = hexamethylmelamine; L-PAM = melphalan; MTX = methotrexate; VP-16 = etoposide.
the latter patients some drugs were excluded because they
caused intolerable side-effects in these patients (Table II).
Thus 15 patients received chemotherapy guided by the
SRCA, whereas in seven patients the treatment was con-
tinued based on the physician's choice.
After relaparotomy, on average seven courses (range 1-20)
of chemotherapy were given to the SRCA group and the
control group also had seven courses (range 1-16). The
'routine' cisplatin-doxorubicin-cyclophosphamide was used
more often in patients whose treatment was not based on the
SRCA (n = 17) than in those who underwent the SRCA
(n = 9) (Tables II and III). Nine of the 22 patients with the
SRCA (41%) and 15 of the 23 control patients (65%) were
treated with the same cytostatic combinations used before the
study operation. Six patients with cancer resistant to all
combinations tested were treated with similar combination to
those employed after primary operation.
Fifteen patients have died in the SRCA group and 17 in
the control group, and this occurred on average 11 months
after reoperation in both groups. Four of 11 patients with
SRCA guided chemotherapy (36%) and seven of 24 patients
with physician's choice of chemotherapy (29%) (patient H.R.
with unevaluable SRCA was also included in this group)
survived at least 3 years (Table IV). After 3 years three
patients with SRCA guided chemotherapy (27%) and six
patients (25%) with physician's choice of chemotherapy were
free of disease.
Discussion
There is a great interest in tests which can be of help in
selection of cytotoxic treatment for recurrent ovarian cancer.
One of them was the human tumour stem cell assay (Ham-86 P. VENESMAA & 0. YLIKORKALA
Table III Cytotoxic treatment of23 control patients before and after
reoperation
Number ofpatients Drug combination Drug combination
before operation after reoperation
14 (6 survived) DDP-A-CTX DDP-A-CTX
1 DDP-A-CTX DDP-CTX
1 DDP-A-CTX DDP-VLB
1 DDP-A-CTX MTX-A-5-FU
2 5-FU-A-CTX DDP-A-CTX
1 5-FU-A-VCR-CTX DDP-A-CTX
1 VCR-A-CTX VCR-A-5-FU
1 VCR-CTX VCR-CTX
1 VCR-CTX DDP-BLEO-VLB
BLEO = bleomycin; VLB = vinblastine; VCR = vincristine, other
abbreviations: see Table II.
Table IV The rates of survival at 3 years' follow-up in patients who
were treated with and without the SRCA test
SRCA guided Physician's choice
chemotherapy ofchemotherapy
Total patients treated 4/11 (36%) 7/24" (29%)
DDP-A-CTX after 3/6 (50%) 7/17 (45%)
reoperation*
Other therapy 1/5 (20%) 0/6 (0%)
DDP-A-CTX = cisplatin-doxorubicine-cyclophosphamide. One
patient with cisplatin-doxorubicin-cyclophosphamide-hexamethyl-
melamine included. "Patient with unevaluable SRCA test included.
burger & Salmon, 1977) which predicted correctly drug resis-
tance in 90-99% of cases (Alberts et al., 1980; Welander et
al., 1983) but failed to detect drug sensitivity in approxi-
mately 40% of cases (Alberts et al., 1980). The clinical
usefulness of this test is limited by inadequate tumour cell
growth in culture (Selby et al., 1983) and the long incubation
period (up to 2-3 weeks) required in the test. The SRCA is
readable in 6 days and it is applicable to test tumour sensi-
tivity to several cytostatics or their combinations (Stratton et
al., 1984; Maenpaa et al., 1985b). Furthermore, this test can
be used to assess the potential effect of cytostatics which
require bioactivation (Stratton et al., 1984).
In spite of the fact that the SRCA was evaluable in the
majority of patients, it could help in guiding the chemo-
therapy only in half of the patients and a considerable por-
tion of patients in both study groups actually received the
same combinations to those used after primary operation.
This was partly due to the fact that some drugs which
appeared effective according to the SRCA could not be used
in patients, because they had caused intolerable side-effects.
There are also several other factors which may explain the
lack of any profound effect of the use of the SRCA on the
survival figures. First, ovarian cancer is a heterogenous
tumour consisting of a number of different cell types, and it
is impossible to guarantee that a small tumour piece taken
blindly at operation was the most representative part of the
cancer. Second, the majority of our patients received as
first-line therapy the combination of cisplatin-doxorubicin-
cyclophosphamide which is one of the most potent drug
combinations used in the treatment of ovarian cancer; this is
also clearly seen from our data. Thus, whatever new chemo-
therapy alternatives were suggested by the use of the SRCA,
they are likely to prove less effective than the combination of
cisplatin-doxorubicin-cyclophosphamide. And third, cancer
cells are known to develop resistance to multiple drugs simul-
taneously, perhaps as a result of cell membrane glycoprotein
which promotes the efflux ofdrugs from cancer cells (Scheper
et al., 1988). In the future when more effective and possibly
more selective antitumour drugs are available, the SRCA
may potentially have a role in the management of advanced
ovarian cancer.
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